We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Canakinumab vs Nicotinamide Riboside: Nicotinamide Riboside has the stronger overall evidence (5.5 vs 4/10); they're alternatives for reduce inflammation — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Nicotinamide Riboside wins 3 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Mostly mechanism / observational
Top outcomes
Verdict
Mostly mechanism / observational
2 of 2 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (1)
Outcomes where both Canakinumab and Nicotinamide Riboside have evidence — compare verdict strength side-by-side.
A prescription biologic, not self-administered for longevity. Approved CAPS dosing is 150 mg subcutaneously every 8 weeks (weight-adjusted in children). The CANTOS cardiovascular regimen was 150 mg subcutaneously every 3 months. There is NO established off-label longevity protocol, and cost is prohibitive.
any
Subcutaneous injection (clinician-administered)
300–500 mg daily
Morning with breakfast, Split dosing (morning and midday) for doses above 500 mg
Nicotinamide Riboside Chloride capsules or powder
Months to years
Weeks
Trial endpoints
Throughout use
1–2 weeks
4–8 weeks
8–16 weeks
4–8 weeks
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
The New England journal of medicine (2017) · Rct · n=10061
CANTOS: randomized, double-blind, placebo-controlled trial in ~10,000 post-MI patients with elevated hsCRP
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.
Lancet (2017) · Rct
Exploratory analysis of the CANTOS cohort — incident and fatal lung cancer as pre-specified secondary endpoints
Canakinumab in combination with docetaxel compared with docetaxel alone for the treatment of advanced non-small cell lung cancer following platinum-based doublet chemotherapy and immunotherapy (CANOPY-2): A multicenter, randomized, double-blind, phase 3 trial.
Lung cancer (Amsterdam, Netherlands) (2024) · Rct · n=237
CANOPY-2: phase 3 randomized, double-blind trial in advanced non-small-cell lung cancer
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Journal of cachexia, sarcopenia and muscle (2025) · Meta analysis
Systematic review and meta-analysis of RCTs evaluating NMN and NR effects on skeletal muscle mass and function
NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Ageing research reviews (2026) · Systematic review
PRISMA-guided systematic review of both preclinical and clinical NAD+ supplementation literature
NAD+ therapy in age-related degenerative disorders: A benefit/risk analysis.
Experimental gerontology (2020) · Systematic review
Systematic review of 147 articles (113 preclinical, 34 clinical) on NAD+ precursor therapy
Based on 8-week RCT showing dose-dependent increases of 22%, 51%, and 142% at 100, 300, and 1000mg respectively. Individual response varies significantly (30% show variable response). NR-SAFE trial confirmed safety up to 2000mg.
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide Riboside has a higher evidence score (5.5/10 vs 4/10) and wins in 3 of 3 categories.
For reduce inflammation, Nicotinamide Riboside has a higher relevance score (65 vs 62).
No known interactions between Canakinumab and Nicotinamide Riboside have been documented in our database. However, always consult a healthcare provider before combining supplements.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.